{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 0, "question": "How many clients does 2U, Inc. have as of December 31, 2023?", "prediction": "The text does not provide a total number of clients for 2U, Inc. as of December 31, 2023. It only mentions that two university clients accounted for 10% or more of the Company's consolidated accounts receivable, but does not give a total client count.", "ground_truth": "2U, Inc. has more than 260 clients as of December 31, 2023."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 1, "question": "As of December 31, 2023, how many executive-sponsored business resource networks (BRNs) did the company have?", "prediction": "As of December 31, 2023, the company had 9 executive-sponsored business resource networks (BRNs).", "ground_truth": "The company had 9 executive-sponsored business resource networks."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 2, "question": "What was the net carrying value of the edX trade name as of December 31, 2023?", "prediction": "The net carrying value of the edX trade name as of December 31, 2023 was $76.7 million.", "ground_truth": "$76.7 million."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 3, "question": "What is the required minimum Recurring Revenues as per the Second Amended Credit Agreement?", "prediction": "$900 million", "ground_truth": "$900 million."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 4, "question": "What is the term expiration year for the lease of 2U, Inc.'s headquarters in Lanham, Maryland?", "prediction": "2028", "ground_truth": "2028."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 6, "question": "What was the translation adjustment loss for foreign currency for the year ended December 31, 2023?", "prediction": "$5.7 million", "ground_truth": "The foreign currency translation adjustment loss was $5.7 million."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 7, "question": "What kind of liabilities does the Company recognize related to uncertain tax positions?", "prediction": "The Company recognizes a liability for unrecognized tax benefits resulting from uncertain tax positions, and also recognizes interest and penalties related to these liabilities as income tax expense.", "ground_truth": "The Company records a liability for unrecognized tax benefits resulting from uncertain tax positions."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 8, "question": "What is the total future minimum payment that 2U, Inc. is obligated to make to university clients as of December 31, 2023?", "prediction": "$17,569 thousand (or $17.6 million)", "ground_truth": "$17,569,000."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 9, "question": "How much stock-based compensation expense was recognized in 2022?", "prediction": "The chunks do not provide a direct answer to the question. However, chunk 0 mentions that \"The total fair value of PRSUs vested during the years ended December 31, 2023, 2022 and 2021, was $0.2 million, $1.9 million, and $71.9 million, respectively.\" \n\nTo find the stock-based compensation expense for 2022, we would need more information, but the total compensation cost related to PRSUs vested in 2022 was $1.9 million. Additionally, the total compensation cost related to the unvested PRSUs not yet recognized as of December 31, 2022, is not explicitly stated, making it impossible to calculate the total stock-based compensation expense for 2022 with the provided information.", "ground_truth": "$80.2 million."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 0, "question": "What is the name of the wholly-owned biotech company formed by 3D Systems in 2022?", "prediction": "Systemic Bio", "ground_truth": "Systemic Bio."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 1, "question": "Who is the company's Executive Vice President and Chief Technology Officer for Regenerative Medicine?", "prediction": "Charles W. Hull.", "ground_truth": "Charles W. Hull."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 2, "question": "How many shares of the company's common stock were surrendered for tax withholding obligations in December 2022?", "prediction": "67,575 shares.", "ground_truth": "67,575 shares of common stock were surrendered for tax withholding obligations in December 2022."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 3, "question": "What was the total revenue for the year ended December 31, 2022?", "prediction": "$538,031 thousand (or $538.0 million)", "ground_truth": "$538.0 million."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 4, "question": "What percentage of 3D Systems' net sales in 2022 was attributable to entities with functional currencies other than the U.S. dollar?", "prediction": "39.4%", "ground_truth": "Approximately 39.4% of net sales."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 5, "question": "What was the net loss income attributable to 3D Systems Corporation for the year ended December 31, 2022?", "prediction": "The net loss attributable to 3D Systems Corporation for the year ended December 31, 2022, was $122,711 thousand, or $(122,711).", "ground_truth": "$(122,711)"}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 6, "question": "What was the net income attributable to 3D Systems Corp. for the year ended December 31, 2021?", "prediction": "$322,052", "ground_truth": "$322,052."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 7, "question": "What was the fair value of cash acquired with the Volumetric acquisition?", "prediction": "$389,000", "ground_truth": "$389."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 8, "question": "What was the total revenue for 3D Systems Corporation for the year ended December 31, 2022?", "prediction": "The total revenue for 3D Systems Corporation for the year ended December 31, 2022 was $538,031 thousand, or $538.0 million.", "ground_truth": "$538,031,000."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 9, "question": "How many shares of restricted stock that vest under specified Company performance measures were included in the outstanding balance as of December 31, 2022?", "prediction": "1,215 shares.", "ground_truth": "1,215 shares of restricted stock."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 0, "question": "What date did Square, Inc. change its corporate name to Block, Inc.?", "prediction": "December 1, 2021.", "ground_truth": "On December 1, 2021, Square, Inc. changed its corporate name to Block, Inc."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 1, "question": "As of December 31, 2023, how many full-time employees did the company have worldwide?", "prediction": "12,985 full-time employees worldwide.", "ground_truth": "The company had 12,985 full-time employees worldwide."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 2, "question": "What portion of Bitcoin does the company hold in offline and air-gapped cold storage?", "prediction": "The vast majority of bitcoin the company holds for itself and its customers is held in offline and air-gapped cold storage.", "ground_truth": "The vast majority of bitcoin we hold for ourselves and our customers is held in offline and air-gapped cold storage."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 3, "question": "As of December 31, 2023, what was the outstanding aggregate principal amount of 2025 Convertible Notes?", "prediction": "$1.0 billion", "ground_truth": "$1.0 billion."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 4, "question": "As of February 16, 2024, how many holders of record were there for Block, Inc.'s Class A common stock?", "prediction": "637", "ground_truth": "As of February 16, 2024, there were 637 holders of record for Block, Inc.'s Class A common stock."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 5, "question": "What was the increase in net cash provided by investing activities for the year ended December 31, 2023?", "prediction": "There was actually a decrease. Net cash provided by investing activities was $1,225,696 in 2022 and $683,201 in 2023, a decrease of $542,495.", "ground_truth": "Net cash provided by investing activities increased by $683.2 million."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 6, "question": "What was Block, Inc.'s total revenue for the year ended December 31, 2023?", "prediction": "$21,915,623", "ground_truth": "$21,915,623,000."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 7, "question": "What was the total net revenue for the year ended December 31, 2023?", "prediction": "$21,915,623", "ground_truth": "$21,915,623,000."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 8, "question": "What was the credit provision for consumer receivables acquired from Afterpay from January 31, 2022, to December 31, 2022?", "prediction": "The provision for credit losses for the period from January 31, 2022, to December 31, 2022, was $203,670 (thousands).", "ground_truth": "$203,670,000."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 9, "question": "What was the total amount of shares repurchased by the Company during the year ended December 31, 2023?", "prediction": "2.5 million shares.", "ground_truth": "2.5 million shares of Class A common stock."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 0, "question": "What was C.H. Robinson Worldwide, Inc.'s total consolidated revenue for the year ended December 31, 2023?", "prediction": "$17,596,443", "ground_truth": "C.H. Robinson Worldwide, Inc.'s total consolidated revenue was $17.6 billion in 2023."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 1, "question": "What was the engagement score from the 2023 survey?", "prediction": "77 percent.", "ground_truth": "77 percent."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 2, "question": "When did Michael P. Zechmeister plan to retire from his position as Chief Financial Officer?", "prediction": "No later than May 31, 2024.", "ground_truth": "No later than May 31, 2024."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 3, "question": "Where is the corporate headquarters of C.H. Robinson Worldwide, Inc. located?", "prediction": "Eden Prairie, Minnesota.", "ground_truth": "The corporate headquarters is in Eden Prairie, Minnesota."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 4, "question": "What was the diluted net income per share for the twelve months ended December 31, 2023?", "prediction": "$2.72", "ground_truth": "$2.72."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 5, "question": "What was the effect of exchange rates on cash and cash equivalents for the year ended December 31, 2023?", "prediction": "The effect of exchange rates on cash and cash equivalents for the year ended December 31, 2023 was a decrease of $3,284,000.", "ground_truth": "A decrease of $3,284,000."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 6, "question": "What was the opinion expressed by the auditing firm regarding C.H. Robinson Worldwide, Inc.'s internal control over financial reporting as of December 31, 2023?", "prediction": "Unqualified opinion, stating that the Company maintained effective internal control over financial reporting in all material respects as of December 31, 2023.", "ground_truth": "The auditing firm expressed that C.H. Robinson Worldwide, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 7, "question": "What was the carrying value of total debt as of December 31, 2023?", "prediction": "$1,580,487 thousand (or $1.58 billion)", "ground_truth": "$1,580,487 thousand."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 8, "question": "What was the total value of shares repurchased by the company in 2023?", "prediction": "$62,778,000", "ground_truth": "$62,778 thousand."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 9, "question": "What was the amount of total restructuring charges recognized for the 2023 South American Restructuring Program?", "prediction": "$21.2 million (or $21,190 thousand)", "ground_truth": "$21.2 million."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 0, "question": "What was the total revenue for Exact Sciences Corporation for the year ended December 31, 2023?", "prediction": "$2,499,766 thousand (or $2.5 billion)", "ground_truth": "$2.50 billion."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 1, "question": "As of December 31, 2023, how many issued patents does the company own in the U.S.?", "prediction": "As of December 31, 2023, the company had 208 issued patents in the U.S.", "ground_truth": "As of December 31, 2023, the company owns 208 issued patents in the U.S."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 2, "question": "What location houses both the headquarters and one of the test facilities?", "prediction": "Madison, Wisconsin.", "ground_truth": "Madison, Wisconsin houses both the headquarters and one of the test facilities."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 3, "question": "What was the settlement amount paid by the company in September 2023 due to a civil investigative demand related to Genomic Health's Medicare billing compliance?", "prediction": "$32.5 million", "ground_truth": "The settlement amount paid in September 2023 was $32.5 million."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 4, "question": "As of December 31, 2023, what is the total indebtedness of the company?", "prediction": "$2.39 billion", "ground_truth": "The total indebtedness is $2.39 billion."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 5, "question": "What is the projected fiscal year range for the Thrive milestone payments related to FDA approval and CMS coverage?", "prediction": "2028 to 2030.", "ground_truth": "The projected fiscal year of payment range is from 2028 to 2030."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 6, "question": "What was the net loss for Exact Sciences Corporation for the year ended December 31, 2023?", "prediction": "$204,149 thousand, or $204.1 million.", "ground_truth": "$204,149,000."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 7, "question": "What was the total revenue of EXACT Sciences Corporation for the year ended December 31, 2023?", "prediction": "The total revenue of EXACT Sciences Corporation for the year ended December 31, 2023, was $2,499,766 (in thousands).", "ground_truth": "$2,499,766,000."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 8, "question": "When will the license agreement with Mayo expire?", "prediction": "The license agreement with Mayo will expire in 2043, or later if certain patent applications are issued, unless terminated earlier according to the agreement's terms.", "ground_truth": "The license agreement will remain in effect until the last of the licensed patents expires in 2039."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 9, "question": "What was the acquisition date fair value of the consideration transferred for the Ashion Acquisition?", "prediction": "$110.0 million.", "ground_truth": "The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 0, "question": "What was the total collaboration revenue recognized during the year ended December 31, 2023?", "prediction": "$38.0 million", "ground_truth": "$38.0 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 1, "question": "What is the expiration date of U.S. Patent No. 7,335,799 covering bempedoic acid, including patent term adjustment?", "prediction": "December 2025, with potential extension to 2030 if the 5-year patent term extension and 6-month pediatric exclusivity are granted.", "ground_truth": "December 2025."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 2, "question": "How many full-time employees did the company have as of December 31, 2023?", "prediction": "240 full-time employees.", "ground_truth": "The company had 240 full-time employees as of December 31, 2023."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 3, "question": "Which regulatory authorities have granted approval for the company’s leading product candidates as an adjunct to diet and statin therapy for the treatment of primary hyperlipidemia?", "prediction": "The FDA, the EC, and Swissmedic.", "ground_truth": "The FDA, the EC, and Swissmedic."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 4, "question": "What is the annual aggregate coverage limit of the product liability insurance for clinical studies?", "prediction": "$10.0 million", "ground_truth": "$10.0 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 5, "question": "What is the senior security interest granted to Oberland under the RIPA?", "prediction": "A senior security interest in certain of the company's assets.", "ground_truth": "A senior security interest in the company's assets."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 6, "question": "What was the net loss for Esperion Therapeutics, Inc. for the year ended December 31, 2023?", "prediction": "The net loss for Esperion Therapeutics, Inc. for the year ended December 31, 2023 was $209,248 thousand, or $2.03 per common share.", "ground_truth": "$209.2 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 7, "question": "What were the net proceeds from the Registered Direct Offering for the year ended December 31, 2023?", "prediction": "The net proceeds from the Registered Direct Offering for the year ended December 31, 2023, were approximately $51.3 million.", "ground_truth": "Approximately $51.3 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 8, "question": "What was the net cash provided by investing activities for the year ended December 31, 2023?", "prediction": "$42.5 million", "ground_truth": "$42,500 thousand."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 9, "question": "What is the effective annual imputed interest rate on the revenue interest liability as of December 31, 2023?", "prediction": "17.6%", "ground_truth": "17.6%."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 1, "question": "What percentage of the company's revenue for the year ended December 31, 2023, came from its insurance verticals?", "prediction": "For the year ended December 31, 2023, the company's revenue from its insurance verticals (Property & Casualty, Health, and Life) was $374,796 ($164,234 + $186,275 + $24,287). The total revenue was $388,149. \n\nThe percentage of revenue from insurance verticals is (374,796 / 388,149) * 100% ≈ 96.6%.", "ground_truth": "96.6% of the revenue."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 2, "question": "What was the aggregate principal amount outstanding under the 2021 Term Loan Facility as of December 31, 2023?", "prediction": "$171.0 million", "ground_truth": "$171.0 million."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 3, "question": "Which cloud infrastructure provider does the company rely on for hosting its platform?", "prediction": "Amazon Web Services (AWS)", "ground_truth": "The company relies on Amazon Web Services (AWS) for hosting its platform."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 4, "question": "What were the low and high closing sales prices of Class A common stock from the IPO through December 31, 2023?", "prediction": "The low and high closing sales prices of Class A common stock from the IPO through December 31, 2023, were $5.36 and $64.11 per share, respectively.", "ground_truth": "The low and high closing sales prices of Class A common stock ranged from $5.36 to $64.11 per share."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 5, "question": "What was the revenue generated by the company for the year ended December 31, 2023?", "prediction": "$388.1 million", "ground_truth": "$388.1 million."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 6, "question": "What was the total Transaction Value for the year ended December 31, 2023?", "prediction": "$593,438 thousand (or $593.4 million)", "ground_truth": "$593,438 thousand."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 7, "question": "What is the total amount of goodwill reported as of December 31, 2023?", "prediction": "$47,739,000", "ground_truth": "$47,739."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 8, "question": "What was the total revenue for MediaAlpha, Inc. for the year ended December 31, 2023?", "prediction": "$388,149 thousand (or $388.1 million)", "ground_truth": "$388,149,000."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 9, "question": "What was the balance of operating lease liabilities classified as non-current as of December 31, 2023?", "prediction": "$1,650 thousand (or $1.65 million)", "ground_truth": "$1,650 thousand."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 0, "question": "What is the primary endpoint that the Phase 2b clinical trial of MM120 met for the treatment of generalized anxiety disorder?", "prediction": "The primary endpoint was statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety (\"HAM-A\") rating scale compared to placebo at Week 4.", "ground_truth": "Statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety (HAM-A) rating scale compared to placebo at Week 4."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 1, "question": "When did the company enter into a collaboration with Dr. Matthias Liechti's lab at UHB?", "prediction": "April 1, 2020.", "ground_truth": "On April 1, 2020."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 2, "question": "What does the Pediatric Research Equity Act require certain NDAs to contain?", "prediction": "The Pediatric Research Equity Act requires certain NDAs to contain data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations.", "ground_truth": "Data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 3, "question": "What is the maximum timeframe for the evaluation of a marketing authorization application in the EU?", "prediction": "210 days, not including clock stops.", "ground_truth": "The maximum timeframe is 210 days, not including clock stops during which applicants respond to questions from the competent authority."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 4, "question": "As of December 31, 2023, how much cash and cash equivalents did the company have?", "prediction": "$99.7 million.", "ground_truth": "$99.7 million."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 5, "question": "What was the amount available for issuance under the shelf registration statement at December 31, 2023?", "prediction": "$99.8 million, with $59.8 million reserved for sales under the at-the-market equity offering program.", "ground_truth": "$99.8 million."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 6, "question": "What may cause material adverse changes in the final clinical trial data?", "prediction": "Audit and verification procedures, changes in patient enrollment, and additional patient data may cause material adverse changes in the final clinical trial data.", "ground_truth": "Material adverse changes in the final data compared to the interim data could significantly harm our business prospects."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 7, "question": "What impact does the failure to gain market access and acceptance of product candidates have on the company's revenue?", "prediction": "The failure to gain market access and acceptance of product candidates will have a material adverse impact on the company's ability to generate revenue, potentially preventing it from providing a satisfactory or any return on investments.", "ground_truth": "It will have a material adverse impact on the ability to generate revenue to provide a satisfactory, or any, return on investments."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 8, "question": "What happens if the pricing of our product candidates is set at unsatisfactory levels or if reimbursement is unavailable or limited?", "prediction": "If pricing is set at unsatisfactory levels or reimbursement is unavailable or limited, the revenue from sales and potential profitability of the product candidates would be negatively affected.", "ground_truth": "Our revenue from sales and the potential profitability of our product candidates in those countries would be negatively affected."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 9, "question": "As of December 31, 2023, how many full-time and part-time employees did the company have?", "prediction": "57", "ground_truth": "57 full-time and part-time employees."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 0, "question": "How many business segments does NVIDIA Corporation report its business results in?", "prediction": "NVIDIA Corporation reports its business results in 2 main segments: Compute & Networking and Graphics, in addition to an \"All Other\" category.", "ground_truth": "NVIDIA Corporation reports its business results in two segments."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 1, "question": "As of the end of fiscal year 2024, how many employees were engaged in research and development at NVIDIA?", "prediction": "22,200 employees were engaged in research and development at NVIDIA as of the end of fiscal year 2024.", "ground_truth": "22,200 employees were engaged in research and development."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 2, "question": "What percentage of NVIDIA's revenue in fiscal year 2024 was generated from sales outside of the United States?", "prediction": "56%", "ground_truth": "56% of NVIDIA's revenue was generated from sales outside of the United States in fiscal year 2024."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 3, "question": "How many employees are in the region impacted by the geopolitical conflict in and around Israel?", "prediction": "Approximately 3,700 employees.", "ground_truth": "There are approximately 3,700 employees in the region."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 4, "question": "What is the symbol under which NVIDIA's common stock is traded?", "prediction": "NVDA", "ground_truth": "NVIDIA's common stock is traded under the symbol NVDA."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 5, "question": "What was NVIDIA's total revenue for fiscal year 2024?", "prediction": "$60,922 million", "ground_truth": "$60.9 billion."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 6, "question": "What was the amount of acquisition termination cost related to the Arm transaction recorded in fiscal year 2023?", "prediction": "$1.4 billion", "ground_truth": "$1.4 billion."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 7, "question": "What was the total shareholders' equity of NVIDIA Corporation as of January 28, 2024?", "prediction": "$42,978 million", "ground_truth": "$42,978 million."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 8, "question": "What is the expected weighted average period over which the unearned stock-based compensation expense will be recognized for RSUs, PSUs, and market-based PSUs as of January 28, 2024?", "prediction": "2.5 years.", "ground_truth": "2.5 years."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 9, "question": "What was NVIDIA's total revenue for the year ended January 28, 2024?", "prediction": "The provided chunks do not explicitly state NVIDIA's total revenue for the year ended January 28, 2024. However, according to chunk 0, the net income for the year ended January 28, 2024, is $29,760 million. To find the total revenue, we would need to refer to the Consolidated Statements of Income, which is not fully provided in the given chunks.", "ground_truth": "$60,922 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 0, "question": "What is the page number for the 'Signature' section in this financial statement?", "prediction": "149-150 and 151.", "ground_truth": "150"}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 1, "question": "What is the expected expiration year of U.S. Patent No. 9,265,740 related to omadacycline?", "prediction": "2030", "ground_truth": "The method of use patent (U.S. 9,265,740) is expected to be extended until October 2030."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 2, "question": "What is the primary business segment for Paratek Pharmaceuticals, Inc. as defined by generally accepted accounting principles?", "prediction": "Paratek Pharmaceuticals, Inc. operates as a single segment.", "ground_truth": "Paratek Pharmaceuticals, Inc. operates its business as a single segment."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 3, "question": "What is the withdrawal quantity of NUZYRA's second procurement accepted by BARDA in December 2022?", "prediction": "2,500 treatment courses.", "ground_truth": "2,500 treatment courses of NUZYRA."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 4, "question": "What is the annual interest rate for the 4.75% Convertible Senior Subordinated Notes issued in April 2018?", "prediction": "4.75%", "ground_truth": "The Notes bear cash interest at the annual rate of 4.75%."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 5, "question": "What was the net loss for the year ended December 31, 2022?", "prediction": "$63,566 thousand (or $63.6 million)", "ground_truth": "$63.6 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 6, "question": "What was the net loss for Paratek Pharmaceuticals, Inc. for the year ended December 31, 2022?", "prediction": "The net loss for Paratek Pharmaceuticals, Inc. for the year ended December 31, 2022 was $63,566,000.", "ground_truth": "$63.6 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 7, "question": "What was Paratek Pharmaceuticals, Inc.'s accumulated deficit through December 31, 2022?", "prediction": "$930,449,000", "ground_truth": "$930.4 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 8, "question": "What was the Company's total cash, cash equivalents and restricted cash as of December 31, 2022?", "prediction": "$34,373,000", "ground_truth": "$34.4 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 9, "question": "What was the total coupon interest expense recognized by the Company for the R-Bridge Loan Agreement in the year ended December 31, 2022?", "prediction": "$4.4 million", "ground_truth": "$4.4 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 0, "question": "Which two reportable segments does Tesla, Inc. operate?", "prediction": "Tesla, Inc. operates two reportable segments: \n\n1. Automotive\n2. Energy generation and storage", "ground_truth": "Automotive and energy generation and storage."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 1, "question": "As of December 31, 2023, what was Tesla's worldwide employee headcount?", "prediction": "140,473", "ground_truth": "140,473."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 2, "question": "As of December 31, 2023, how much aggregate principal amount of indebtedness did Tesla and its subsidiaries have outstanding?", "prediction": "$4.68 billion.", "ground_truth": "$4.68 billion."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 3, "question": "What was the intra-day trading high and low of the company's common stock over the last 52 weeks?", "prediction": "The intra-day trading high was $299.29 per share and the low was $152.37 per share.", "ground_truth": "The intra-day trading high was $299.29 per share and the low was $152.37 per share."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 4, "question": "What was the automotive sales revenue for the year ended December 31, 2023?", "prediction": "$78,509 million.", "ground_truth": "$78,509 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 5, "question": "What was Tesla, Inc.'s total revenue for the year ended December 31, 2023?", "prediction": "$96,773 million", "ground_truth": "$96,773 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 6, "question": "What was the total cash and cash equivalents and restricted cash as of December 31, 2023?", "prediction": "$17,189 million.", "ground_truth": "$17,189 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 7, "question": "What was the carrying value of digital assets, net, as of December 31, 2023?", "prediction": "$184 million", "ground_truth": "$184 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 8, "question": "What was Tesla's total revenue for the year ended December 31, 2023?", "prediction": "$96,773 million", "ground_truth": "$96,773 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 9, "question": "Which independent registered public accounting firm audited the effectiveness of internal control over financial reporting as of December 31, 2023?", "prediction": "PricewaterhouseCoopers LLP.", "ground_truth": "PricewaterhouseCoopers LLP."}
